

Synthesis of Unnatural 1-Methyl-2-quinolone Derivatives

Motoki ASAHARA, Taku KATAYAMA, Yasuo TOHDA, Nagatoshi NISHIWAKI,* and Masahiro ARIGA*

Department of Chemistry, Osaka Kyoiku University; 4-698-1 Asahigaoka, Kashiwara, Osaka 582-8582, Japan.

Received August 9, 2004; accepted September 1, 2004; published online September 2, 2004

Unnatural 1-methyl-2-quinolone derivatives were synthesized by regioselective C–C bond formation. When 1-methyl-3,6,8-trinitro-2-quinolone (TNQ) was treated with enamines, nucleophilic addition readily occurred at the 4-position, and succeeding hydrolysis of enamine moiety followed by elimination of nitrous acid furnished 4-acylmethyl-1-methyl-6,8-dinitro-2-quinolones. The same products could be prepared by the reaction of TNQ with ketones in the presence of triethylamine. The present reaction enabled the introduction of various kinds of acylmethyl groups substituted with alkyl, aryl or hetaryl groups.

Key words 1-methyl-2-quinolone; trinitroquinolone; *cine*-substitution; regioselective C–C bond formation

The 1-methyl-2-quinolone (MeQone) skeleton has been found in more than 300 quinoline alkaloids those are mostly isolated from the Rutaceae family.^{1–15} Since these alkaloids show physiological activities, many researchers have energetically studied the isolation, the structural determination and total syntheses of quinoline alkaloids containing the MeQone skeleton.^{4–15} From the viewpoint for the drug design, it is also demanded to synthesize hitherto unknown unnatural MeQone derivatives and to develop new methods for functionalization of the MeQone framework.^{16–32} Especially, modification of the pyridone moiety in the MeQone is highly important because most of the naturally occurring MeQones have substituents at the 3 and/or the 4-position. Mainly used methods for functionalization of the MeQone involve the activation by the pre-introduced substituents such as hydroxyl, alkoxy and amino groups,^{4–15} which compose partial structures of newly constructed skeleton. Meanwhile, direct functionalization methods of MeQone were recently attracted.^{16–29} As one of the methodologies, Fujita and co-workers prepared phenanthridine derivatives by Diels–Alder reaction of electron-rich dienes with MeQone having an electron-withdrawing group at the 3 or 4-position.^{30–32}

In our course of study on electron-deficient quinolones, 1-methyl-3,6,8-trinitro-2-quinolone (TNQ) was found to be highly reactive, which realized direct functionalization of the MeQone.³³ The steric repulsion between the 8-nitro and the 1-methyl groups activates the pyridone ring of TNQ, which

reveals nitroalkene property rather than aromatic one.³⁴ When TNQ was allowed to react with tertiary amine in acetonitrile, dimer of TNQ connected at the 3- and 4'-positions was obtained at room temperature, and denitration on the pyridone ring occurred at the elevated temperature leading to **1**.³⁵ On the other hand, 4-functionalized 6,8-dinitro-2-quinolones, were readily formed upon treatment of TNQ with 1,3-dicarbonyl compounds in the presence of triethylamine, in which regioselective C–C bond formation at the 4-position is achieved.³³ Although the present *cine*-substitution is useful for direct functionalization of the quinolone ring, only 1,3-dicarbonyl compounds were usable. Thus, it is one of the important projects to enable the employment other nucleophiles, which provides a new methodology for the quinolone chemistry. Since we succeed to introduce a variety of acylmethyl groups at the 4-position of the MeQone skeleton, results will be represented in this paper.

Results and Discussion

Enamines were employed as the carbon nucleophiles instead of 1,3-dicarbonyl compounds. When TNQ was treated with 1-morpholino-1-phenylethene **2a** in the presence of water at room temperature, 4-benzoylmethyl-6,8-dinitro-2-quinolone **3a** was isolated (Table 1, run 1). This reaction was considerably affected by steric hindrance at the β -position of enamines, namely the presence of substituent R². When enamines **2b** and **2c** were employed, morpholinium salts **4b** and **4c** were obtained instead of *cine*-substituted products **3b** and **3c** (runs 2 and 3). Cyclic enamine **2d** also reacted with




Chart 1. Functionalized MeQones derived from TNQ

Table 1. Reactions of TNQ with Enamines

| Run | Enamine | Enamine | | | Time/d | Product | Yield/% |
|-----|-----------|------------------------------------|----------------|----------------|--------|-----------|---------|
| | | R ¹ | R ² | R ³ | | | |
| 1 | 2a | Ph | H | H | 3 | 3a | 37 |
| 2 | 2b | Ph | Me | H | 3 | 4b | 43 |
| 3 | 2c | Ph | Ph | H | 1 | 4c | 98 |
| 4 | 2d | –(CH ₂) ₃ – | | H | 2 | 4d | 40 |
| 5 | 2e | H | Me | Me | 0.5 | 4e | 98 |

* To whom correspondence should be addressed. e-mail: ariga@cc.osaka-kyoiku.ac.jp




Chart 2. A Plausible Mechanism for Reactions of TNQ with Enamines





Chart 3. Trap of Meisenheimer Complex as Morpholinium Nitronate

TNQ to give corresponding salt **4d** (run 4). Enamine **2e** derived from aldehyde was more reactive leading to salt **4e** in an excellent yield within short reaction time even though **2e** had two methyl groups at the reaction site (run 5).

A plausible mechanism for these reactions of TNQ with enamines is illustrated in Chart 2. An enamine attacks at the electron deficient 4-position of TNQ giving Meisenheimer complex **6**. The following hydrolysis of the immonium moiety leads to 3,4-dihydroquinolone **7**, and morpholine is liberated during this process. Deprotonation at the 3-position by morpholine gives morpholinium salt **4**. On the other hand, deprotonation at the 4-position causes elimination of nitrous acid to afford *cine*-substituted product **3**. When substituent at the 4-position of dihydroquinolone **7** is sterically hindered, the former reaction is preferable than the latter one.


Intermediate dihydroquinolone **5b** was isolated in the reaction conducted under dried conditions to avoid hydrolysis. The result strongly supported our proposed addition-elimination mechanism for *cine*-substitution.³³⁾ While it was somewhat difficult to isolate adduct **5** because of hydrolysis, effective trap of **5** as morpholinium salt **8f** was achieved by addition of extra morpholine to the reaction mixture. Dihydroquinolone **7f** could be obtained by acidification of **8f** despite in a low yield, and the major part of **8f** was converted to TNQ with elimination of the ketone moiety at the 4-position. Dihydroquinolones **7b**, **7c** and **7e** were respectively isolated in good yields when morpholinium salts **4b**, **4c** and **4e** were acidified with hydrochloric acid.

Results mentioned so far prompted us to employ less reactive ketones as the nucleophiles. In this reaction, addition of base seemed to be necessary for accelerating enolization of ketones **9** and for assisting elimination of nitrous acid from intermediate dihydroquinolone **7**. When TNQ was treated with acetophenone **9a** in the presence of triethylamine, *cine*-substitution readily proceeded to afford 4-(benzoylmethyl)quinolone **3a** in a good yield. The present reaction was applicable to other ketones, and results were summarized in Table 2 and Chart 4. This reaction was applicable to α -monosubstituted acetophenones **9b** and **9c** (Table 2, runs 2 and 3), however α,α -disubstituted acetophenone **9l** caused no change (run 5). Bicyclic ketone, tetralone **9m**, also reacted with TNQ affording **3m** in a moderate yield (run 6). Aliphatic ketones **9d** and **9f–j** showed similar reactivity to afford corresponding 4-substituted dinitroquinolones **3d** and **3f–j** (runs 7–10 and Chart 4). When unsymmetrical butanone **9h** was used, thermodynamically controlled enol was more reactive than kinetically controlled one, and leading to **3h** as a major product. The yield of *cine*-substituted product was considerably lowered in the case of 3-pentanone **9j** because of steric hindrance, and the competitive addition of triethylamine at the 4-position was preferred, which caused denitration to give 6,8-dinitroquinolone **1** (run 10).³⁵⁾ Aldehyde **9e** was reactive to afford *cine*-substituted product **3e** despite the presence of two methyl groups at the reaction site. Furthermore, the present reaction realized the introduction of heteroaryl groups to the MeQone skeleton. 2-

Table 2. *cine*-Substitution of TNQ with Ketones


| Run | Ketone | | | Time/h | Yield/% |
|-----|----------------|---|----------------|--------|--------------------------------|
| | R ¹ | R ² | R ³ | | |
| 1 | 9a | Ph | H | 2.5 | 83 (3a) |
| 2 | 9b | Ph | Me | 3.5 | 77 (3b) |
| 3 | 9c | Ph | Ph | 3.5 | 69 (3c) |
| 4 | 9k | 4-MeC ₆ H ₄ | H | 2.5 | 59 (3k) |
| 5 | 9l | Ph | Me | 6 | 0 ^{a)} (3l) |
| 6 | 9m | -(<i>o</i> -C ₆ H ₄)CH ₂ CH ₂ - | H | 2 | 52 (3m) |
| 7 | 9d | -(CH ₂) ₃ - | H | 2 | 58 (3d) |
| 8 | 9f | -(CH ₂) ₄ - | H | 2 | 82 (3f) |
| 9 | 9g | Me | H | 3.5 | 83 (3g) |
| 10 | 9j | Et | Me | 4 | 18 ^{a)} (3j) |
| 11 | 9e | H | Me | 5 | 41 (3e) |
| 12 | 9n | 2-Pyridyl | H | 2.5 | 74 (3n) |
| 13 | 9o | 2-Furyl | H | 3 | 45 (3o) |

a) 6,8-Dinitroquinolone **1** was isolated in 41% (run 5) and 73% (run 10) yields.

Chart 4. Reaction of TNQ with 2-Butanone **9h**

Acetylpyridine **9n** and 2-acetylfuran **9o** showed similar reactivity to furnish dihydroquinolones **3n** and **3o** (runs 12 and 13).

In summary, TNQ was shown to be an excellent precursor for unnatural MeQone derivatives having an acylmethyl group **3** and their related compounds. Enamines readily reacted with TNQ at room temperature to give 4-acylmethylquinolones **3**, which were formed by hydrolysis of adduct **6** and dihydroquinolones **7**. Furthermore, ketones were usable for this reaction as the nucleophile instead of enamines though the reaction should be conducted in the presence of triethylamine at higher temperature. In the present reaction, aliphatic or alicyclic ketones could be used, and introduction of acylmethyl or 2-oxocycloalkyl groups was achieved at the 4-position of 6,8-dinitroquinolones. Arylmethyl and heteroarylmethyl groups could be also introduced by using aryl and heteroaryl ketones.

These reactions required only simple experimental manipulations, and the C–C bond formation at the 4-position of the MeQone skeleton was performed regioselectively. Hence, this reaction would provide a new methodology for functionalization of the MeQone skeleton.

Experimental

General The melting points were determined on a Yanaco micro-melting-points apparatus, and were uncorrected. ¹H-NMR spectra were measured on a Bruker DPX-400 at 400 MHz and on a Hitachi R1200 at 60 MHz with TMS as an internal standard. ¹³C-NMR spectra were measured on a Bruker DPX-400 at 100 MHz with TMS as an internal standard, and assignments of signals (s, d, t and q) were made from DEPT experiments. IR spectra were

recorded on a Horiba FT-200 IR spectrometer. Elemental microanalyses were performed using a Yanaco MT-3 CHN coder. All the reagents and solvents were commercially available and used as received. All of reactions were carried out under ambient atmosphere. Column chromatography was performed using Wakogel C-200.

1-Methyl-3,6,8-trinitro-2-quinolone (TNQ) Following the procedure described for 1-methyl-2-pyridone,³⁶⁾ MeQone was prepared by oxidation of 1-methylquinolinium ion using potassium ferricyanide (III) under alkaline conditions after methylation of quinoline with dimethyl sulfate using the three times diluted solution. Nitration of MeQone with fuming nitric acid (d=1.52) afforded TNQ in 90% yield.³³⁾

Typical Procedure for the Reaction of TNQ with Enamines in the Presence of Water To a solution of TNQ (0.28 g, 0.95 mmol) and water (0.85 g, 47.2 mmol) in acetonitrile (25 ml), was added a solution of 1-morpholino-1-phenylethene **2a** (0.26 g, 1.37 mmol) in acetonitrile (10 ml) at room temperature, and the mixture was stirred for 3 d. Generated precipitates were collected by filtration to afford 4-benzoylmethyl-6,8-dinitro-1-methyl-2-quinolone (**3a**) as pale yellow powder (0.13 g, 0.35 mmol, 37%) mp 229–230 °C (dec.). IR (KBr/cm⁻¹) 1682, 1670, 1529, 1342; ¹H-NMR (400 MHz, DMSO-*d*₆) δ: 3.37 (s, 3H), 5.05 (s, 2H), 6.98 (s, 1H), 7.62 (dd, *J*=7.2, 7.4 Hz, 2H), 7.73 (t, *J*=7.4 Hz, 1H), 8.13 (d, *J*=7.2 Hz, 2H), 8.71 (d, *J*=2.5 Hz, 1H), 8.89 (d, *J*=2.5 Hz, 1H); ¹³C-NMR (100 MHz, DMSO-*d*₆) δ: 34.4 (q), 41.8 (t), 122.2 (d), 123.6 (s), 124.9 (d), 125.1 (d), 128.4 (d), 128.7 (d), 133.7 (d), 135.9 (s), 137.6 (s), 138.7 (s), 139.9 (s), 145.5 (s), 161.2 (s), 195.9 (s). *Anal.* Calcd for C₁₈H₁₃N₃O₆: C, 58.85; H, 3.57; N, 11.44. Found: C, 58.67; H, 3.45; N, 11.50.

Reactions of TNQ with other enamines were conducted in the same way.

Morpholinium 4-(1-Benzoyl-ethyl)-3,4-dihydro-6,8-dinitro-1-methyl-2-oxoquinoline-3-nitronate (4b) Pale yellow powder. mp 160–162 °C (dec.). IR (KBr/cm⁻¹) 1675, 1657, 1537, 1522, 1358, 1336; ¹H-NMR (400 MHz, CDCl₃) δ: 1.06 (d, *J*=6.7 Hz, 3H), 1.2–2.5 (br, 2H), 3.03 (s, 3H), 3.2–3.4 (m, 4H), 3.9–4.1 (m, 4H), 4.2–4.3 (m, 1H), 5.16 (d, *J*=3.6 Hz, 1H), 7.51 (m, 2H), 7.63 (t, *J*=7.5 Hz, 1H), 7.92 (d, *J*=2.2 Hz, 1H), 8.16 (d, *J*=8.0 Hz, 2H), 8.44 (d, *J*=2.2 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ: 12.3 (q), 34.8 (q), 43.2 (d), 43.8 (t), 45.3 (d), 64.1 (t), 108.0 (s), 120.5 (d), 126.7 (d), 128.7 (d), 129.0 (d), 131.5 (s), 133.7 (s), 136.1 (s), 138.6 (s), 141.0 (s), 162.9 (s), 200.6 (s). *Anal.* Calcd for C₂₃H₂₅N₅O₉: C, 53.59; H, 4.89; N, 13.59. Found: C, 53.39; H, 4.88; N, 13.72.

Morpholinium 4-(α -Benzoylbenzyl)-3,4-dihydro-6,8-dinitro-1-methyl-2-oxoquinoline-3-nitronate (4c) Yellow powder. mp 132–133 °C (dec.). IR (KBr/cm⁻¹) 1684, 1651, 1535, 1371, 1335; ¹H-NMR (400 MHz, CDCl₃) δ: 2.31 (s, 3H), 3.26–3.29 (m, 4H), 3.96–3.99 (m, 4H), 4.97 (d, *J*=2.3 Hz, 1H), 5.56 (d, *J*=2.3 Hz, 1H), 6.84 (dd, *J*=6.4, 3.4 Hz, 2H), 7.11–7.12 (m, 3H), 7.25–7.46 (m, 3H), 7.92 (d, *J*=7.4 Hz, 2H), 8.42 (d, *J*=2.6 Hz, 1H), 9.03 (d, *J*=2.6 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ: 34.1 (q), 42.0 (d), 43.5 (t), 57.8 (d), 63.8 (t), 109.1 (s), 120.3 (d), 127.9 (d), 128.5 (d), 128.6 (d), 128.9 (d), 129.1 (d), 129.2 (d), 131.8 (s), 133.1 (d), 135.3 (s), 135.9 (s), 138.5 (s), 139.6 (s), 141.1 (s), 162.7 (s), 198.2 (s). *Anal.* Calcd for C₂₈H₂₇N₅O₉: C, 58.22; H, 4.71; N, 12.13. Found: C, 58.04; H, 4.57; N, 11.94.

Morpholinium 3,4-Dihydro-6,8-dinitro-1-methyl-4-(2-oxocyclopentyl)-2-oxoquinoline-3-nitronate (4d) Yellow powder. mp 126–128 °C (dec.). IR (KBr/cm⁻¹) 1732, 1660, 1525, 1338; ¹H-NMR (400 MHz, CDCl₃) δ: 1.41–1.44 (m, 1H), 1.76–1.82 (m, 1H), 1.94–2.04 (m, 3H), 2.26–2.32 (m, 1H), 2.54–2.59 (m, 1H), 3.13 (s, 3H), 3.27 (br, *J*=4.6 Hz, 4H), 3.98 (br, *J*=4.6 Hz, 4H), 5.14 (d, *J*=4.7 Hz, 1H), 8.29 (d, *J*=2.5 Hz, 1H), 8.49 (d, *J*=2.5 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ: 20.4 (t), 26.0 (t), 34.5 (q), 38.1 (t), 39.3 (d), 43.6 (t), 53.4 (d), 64.0 (t), 108.0 (s), 120.4 (d), 126.7 (d), 132.8 (s), 138.7 (s), 139.4 (s), 141.4 (s), 162.8 (s), 217.1 (s). *Anal.* Calcd for C₁₉H₂₃N₅O₉: C, 49.03; H, 4.98; N, 15.05. Found: C, 49.43; H, 5.10; N, 14.93.

Morpholinium 3,4-Dihydro-4-(1,1-dimethyl-2-oxoethyl)-6,8-dinitro-1-methyl-2-oxoquinoline-3-nitronate (4e) Yellow powder. mp 175–177 °C (dec.). IR (KBr/cm⁻¹) 1718, 1659, 1543, 1524, 1338; ¹H-NMR (400 MHz, CDCl₃) δ: 0.78 (s, 3H), 0.97 (s, 3H), 2.87 (s, 3H), 3.00–3.15 (m, 4H), 3.2–4.0 (br, 2H), 3.75–3.76 (m, 4H), 4.96 (s, 1H), 8.39 (s, 1H), 8.57 (s, 1H), 9.48 (s, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ: 17.5 (q), 19.3 (q), 33.5 (q), 43.2 (t), 44.8 (d), 52.4 (t), 63.6 (s), 102.8 (s), 120.4 (d), 126.9 (d), 131.5 (s), 137.7 (s), 139.7 (s), 140.06 (s), 161.2 (s), 203.7 (d). *Anal.* Calcd for C₁₈H₂₃N₅O₉: C, 47.68; H, 5.11; N, 15.45. Found: C, 47.55; H, 5.16; N, 15.51.

3,4-Dihydro-1-methyl-4-(1-morpholino-1-phenyl-2-propenyl)-3,6,8-trinitro-2-oxoquinoline (5b) Pale yellow needles. mp 157–158 °C (dec.). IR (KBr/cm⁻¹) 1718, 1653, 1566, 1541, 1344; ¹H-NMR (60 MHz, CDCl₃) δ:

1.83 (s, 3H), 2.73 (t, $J=4.5$ Hz, 4H), 3.14 (s, 3H), 3.73 (t, $J=4.5$ Hz, 4H), 4.33 (d, $J=13.0$ Hz, 1H), 5.56 (d, $J=13.0$ Hz, 1H), 6.9–7.5 (m, 5H), 8.42 (d, $J=2.4$ Hz, 1H) 8.62 (d, $J=2.4$ Hz, 1H).

Morpholinium 3,4-Dihydro-6,8-dinitro-1-methyl-4-(2-morpholino-2,3-cyclohexenyl)-2-oxoquinoline-3-nitronate (8f) To a solution of TNQ (0.60 g, 2.04 mmol) in acetonitrile (40 ml), was added a solution of 1-morpholino-1-cyclohexene **2f** (0.66 g, 3.95 mmol) and morpholine (0.18 g, 2.07 mmol) in acetonitrile (10 ml), and the resultant mixture was stirred at room temperature for 4 h. Morpholinium salt **8f** was precipitated as orange powder during the reaction, and was collected by filtration (1.05 g, 1.93 mmol, 95%) mp 143–145 °C (dec.). IR (KBr/ cm^{-1}) 1653, 1539, 1333; $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 0.95–0.98 (m, 1H), 1.16–1.25 (m, 2H), 1.61–2.00 (m, 3H), 2.60–2.75 (m, 2H), 3.11 (s, 3H), 3.00–3.30 (m, 1H), 3.17–3.30 (m, 4H), 3.31–3.51 (m, 2H), 3.80–4.03 (m, 8H), 5.05 (br t, $J=3.0$ Hz, 1H), 5.16 (d, $J=3.0$ Hz, 1H), 8.45 (d, $J=2.3$ Hz, 1H), 8.48 (d, $J=2.3$ Hz, 1H); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3) δ : 21.1 (t), 24.7 (t), 25.0 (t), 34.9 (q), 38.7 (d), 41.2 (d), 44.6 (t), 49.4 (t), 65.3 (t), 67.3 (t), 109.4 (d), 109.5 (s), 119.9 (d), 127.8 (d), 129.3 (s), 138.3 (s), 139.7 (s), 141.0 (s), 144.6 (s), 163.4 (s). *Anal.* Calcd for $\text{C}_{24}\text{H}_{32}\text{N}_6\text{O}_9 \cdot \text{CH}_3\text{CN}$: C, 52.96; H, 5.98; N, 16.63. Found: C, 52.96; H, 6.10; N, 16.65.

3,4-Dihydro-1-methyl-4-(2-oxocyclohexyl)-3,6,8-trinitro-2-quinolone (7f) To a solution of morpholinium salt **8f** (0.38 g, 0.693 mmol) in methanol (30 ml), 1 M hydrochloric acid (1.4 ml, 1.4 mmol) was added, and the mixture was stirred for 15 min. Generated precipitates were collected by filtration, and were washed with methanol (15 ml) to give a mixture of isomeric **7f** and TNQ as white powder (0.21 g, *trans-7f*, 10%, *cis-7f*, 4%, TNQ, 83% yields. These values were determined by $^1\text{H-NMR}$). *trans-7f* $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 1.20–2.50 (m, 8H), 2.84–2.90 (m, 1H), 3.30 (s, 3H), 4.49 (dd, $J=2.1$, 8.0 Hz, 1H), 5.85 (d, $J=2.1$ Hz, 1H), 8.62 (d, $J=2.6$ Hz, 1H), 8.66 (d, $J=2.6$ Hz, 1H). *cis-7f* $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 1.20–2.50 (m, 8H), 3.00–3.06 (m, 1H), 3.19 (s, 3H), 4.55 (dd, $J=1.8$, 6.1 Hz, 1H), 5.94 (d, $J=1.8$ Hz, 1H), 8.65 (s, 2H).

4-(1-Benzoyl-ethyl)-3,4-dihydro-1-methyl-3,6,8-trinitro-2-quinolone (7b) To a solution of morpholinium salt **4b** (0.47 g, 1.0 mmol) in methanol (30 ml), 1 M hydrochloric acid (1.5 ml, 1.5 mmol) was added, and the mixture was stirred for 3 d. Generated precipitates were collected by filtration, and were washed with methanol (15 ml) to give **7b** as white powder (0.27 g, 69% yield). mp 140.5–141.5 °C (dec.). IR (KBr/ cm^{-1}) 1689, 1653, 1568, 1545, 1384; $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 1.32 (d, $J=7.2$ Hz, 1H), 3.30 (s, 3H), 3.64 (dq, $J=9.0$, 7.2 Hz, 1H), 4.42 (dd, $J=9.0$, 2.2 Hz, 1H), 5.34 (d, $J=2.2$ Hz, 1H), 7.49–7.63 (m, 2H), 7.65 (t, $J=6.3$ Hz, 1H), 7.84–7.86 (m, 2H), 8.38 (d, $J=2.6$ Hz, 1H), 8.63 (d, $J=2.6$ Hz, 1H); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3) δ : 17.4 (q), 34.8 (q), 41.3 (d), 44.2 (d), 84.3 (d), 121.8 (d), 127.9 (d), 128.4 (d), 128.7 (s), 128.9 (s), 129.3 (d), 134.6 (d), 134.7 (s), 138.6 (s), 142.7 (s), 155.6 (s), 199.4 (s). *Anal.* Calcd for $\text{C}_{19}\text{H}_{16}\text{N}_4\text{O}_8$: C, 53.27; H, 3.77; N, 13.08. Found: C, 52.99; H, 3.68; N, 12.90.

Acidification of **4c** and **4e** was performed in a similar way.

4-(α -Benzoylbenzyl)-3,4-dihydro-1-methyl-3,6,8-trinitro-2-quinolone (7c) Reaction time 1 d, 97% yield. White powder. mp 143–144 °C (dec.). IR (KBr/ cm^{-1}) 1684, 1653, 1574, 1549, 1342; $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 3.12 (s, 3H), 4.58 (d, $J=8.3$ Hz, 1H), 4.86 (dd, $J=8.3$, 2.0 Hz, 1H), 5.48 (d, $J=2.0$ Hz, 1H), 6.93–6.95 (m, 2H), 7.23–7.26 (m, 3H), 7.35–7.39 (m, 2H), 7.51 (t, $J=7.4$ Hz, 1H), 7.82–7.83 (m, 2H), 7.85 (d, $J=2.6$ Hz, 1H), 8.50 (d, $J=2.6$ Hz, 1H); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3) δ : 34.5 (q), 44.3 (d), 54.5 (d), 85.0 (d), 121.4 (d), 128.4 (d), 128.5 (s), 128.6 (d), 128.9 (d), 129.0 (d), 129.3 (d), 129.8 (d), 133.5 (s), 134.2 (s), 134.9 (s), 138.5 (s), 139.8 (s), 142.3 (s), 159.3 (s), 195.2 (s). *Anal.* Calcd for $\text{C}_{24}\text{H}_{18}\text{N}_4\text{O}_8$: C, 58.77; H, 3.70; N, 11.43. Found: C, 58.81; H, 3.70; N, 11.32.

3,4-Dihydro-4-(1,1-dimethyl-2-oxoethyl)-1-methyl-3,6,8-trinitro-2-quinolone (7e) Reaction time 12 h, 99% yield. Pale yellow needles. mp 173–175 °C (dec.). IR (KBr/ cm^{-1}) 1720, 1653, 1560, 1541, 1344; $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 1.15 (s, 3H), 1.21 (s, 3H), 3.24 (s, 3H), 4.33 (d, $J=1.6$ Hz, 1H), 5.43 (d, $J=1.6$ Hz, 1H), 8.35 (d, $J=2.5$ Hz, 1H), 8.63 (d, $J=2.5$ Hz, 1H), 9.41 (s, 1H); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3) δ : 19.7 (q), 20.2 (q), 34.8 (q), 45.8 (d), 48.2 (s), 83.7 (d), 109.3 (s), 121.9 (s), 125.9 (d), 127.5 (s), 128.9 (d), 139.2 (s), 160.0 (s), 200.8 (s). *Anal.* Calcd for $\text{C}_{14}\text{H}_{14}\text{N}_4\text{O}_8$: C, 45.90; H, 3.85; N, 15.30. Found: C, 46.21; H, 3.84; N, 15.04.

6,8-Dinitro-1-methyl-4-[(2-(4-methylphenyl)-2-oxoethyl)-2-quinolone (3k) To a solution of TNQ (0.29 g, 0.99 mmol) and 4-methylacetophenone (6.95 g, 51.80 mmol) in acetonitrile (15 ml), was added a solution of triethylamine (0.20 g, 1.98 mmol) in acetonitrile (5 ml), and the resultant mixture was heated at 70 °C for 2.5 h. After removal of the solvent, the reaction mixture was extracted with chloroform (30 ml \times 3), and the organic layer was dried over sodium sulfate and concentrated. The residue was treated with

column chromatography on silica gel to give *cine*-substituted product **3k** (eluted with chloroform. 0.20 g, 0.51 mmol, 52%) as pale yellow powder mp 260–261 °C (dec.). IR (KBr/ cm^{-1}) 1670, 1535, 1524, 1344; $^1\text{H-NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ : 2.46 (s, 3H), 3.40 (s, 3H), 4.96 (s, 2H), 6.96 (s, 1H), 7.39 (d, $J=8.1$ Hz, 2H), 8.02 (d, $J=8.1$ Hz, 2H), 8.71 (d, $J=2.5$ Hz, 1H), 8.85 (d, $J=2.5$ Hz, 1H); $^{13}\text{C-NMR}$ (100 MHz, $\text{DMSO}-d_6$) δ : 21.2 (q), 34.3 (q), 41.7 (t), 121.8 (d), 123.6 (s), 124.9 (d), 128.4 (d), 129.1 (d), 133.2 (s), 137.4 (s), 138.5 (s), 139.7 (s), 144.1 (s), 145.2 (s), 161.0 (s), 194.9 (s). One signal was lacked because of overlap. *Anal.* Calcd for $\text{C}_{19}\text{H}_{15}\text{N}_3\text{O}_6$: C, 59.84; H, 3.97; N, 11.02. Found: C, 59.90; H, 3.84; N, 11.05.

Reactions of TNQ with other ketones or aldehyde were similarly conducted.

4-(1-Benzoyl-ethyl)-6,8-dinitro-1-methyl-2-oxo-quinoline (3b) Pale yellow needles. mp 184–185 °C (dec.). IR (KBr/ cm^{-1}) 1674, 1537, 1524, 1346; $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 1.71 (d, $J=7.0$ Hz, 3H), 3.46 (s, 3H), 5.15 (q, $J=7.0$ Hz, 1H), 6.84 (s, 1H), 7.52 (dd, $J=7.4$, 7.4 Hz, 2H), 7.64 (t, $J=7.4$ Hz, 1H), 7.98 (d, $J=7.4$ Hz, 2H), 8.70 (d, $J=2.5$ Hz, 1H) 8.76 (d, $J=2.5$ Hz, 1H); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3) δ : 17.2 (q), 34.8 (q), 43.0 (d), 122.0 (d), 122.7 (d), 122.9 (s), 123.8 (d), 128.5 (d), 129.3 (d), 134.3 (d), 134.9 (s), 138.4 (s), 139.5 (s), 140.3 (s), 148.8 (s), 161.5 (s), 197.8 (s). *Anal.* Calcd for $\text{C}_{19}\text{H}_{15}\text{N}_3\text{O}_6 \cdot 1/3\text{H}_2\text{O}$: C, 58.92; H, 4.08; N, 10.85. Found: C, 58.52; H, 3.77; N, 11.13.

4-(α -Benzoylbenzyl)-6,8-dinitro-1-methyl-2-quinolone (3c) Pale yellow needles. mp 249–251 °C (dec.). IR (KBr/ cm^{-1}) 1680, 1662, 1543, 1527, 1346; $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 3.47 (s, 3H), 6.37 (s, 1H), 6.47 (s, 1H), 7.32–7.34 (m, 2H), 7.40–7.51 (m, 4H), 7.63 (dd, $J=7.4$, 7.4 Hz, 2H), 8.01–8.03 (m, 2H), 8.57 (d, $J=2.5$ Hz, 1H), 8.67 (d, $J=2.5$ Hz, 1H); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3) δ : 34.9 (q), 56.2 (d), 121.7 (d), 123.2 (d), 123.4 (s), 126.4 (d), 128.9 (d), 129.1 (d), 129.2 (d), 129.6 (d), 130.0 (d), 133.6 (s), 134.4 (d), 135.2 (s), 138.1 (s), 139.4 (s), 140.2 (s), 147.9 (s), 161.6 (s), 195.6 (s).

6,8-Dinitro-1-methyl-4-(2-oxocyclopentyl)-2-quinolone (3d) Pale yellow needles. mp 169–170 °C (dec.). IR (KBr/ cm^{-1}) 1738, 1674, 1539, 1520, 1335; $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 2.11–2.19 (m, 1H), 2.20–2.37 (m, 2H), 2.4–2.7 (m, 3H), 3.47 (s, 3H), 3.91 (dd, $J=10.8$, 8.9 Hz, 1H), 6.77 (s, 1H), 8.70 (d, $J=2.5$ Hz, 1H), 8.73 (d, $J=2.5$ Hz, 1H); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3) δ : 20.7 (t), 29.3 (t), 34.9 (q), 38.3 (t), 50.9 (d), 121.9 (d), 123.7 (s), 124.8 (d), 138.2 (s), 139.2 (s), 140.1 (s), 146.2 (s), 161.7 (s), 213.3 (s). One signal was lacked because of overlap. *Anal.* Calcd for $\text{C}_{15}\text{H}_{13}\text{N}_3\text{O}_6 \cdot 1/4\text{H}_2\text{O}$: C, 53.65; H, 4.05; N, 12.51. Found: C, 53.46; H, 3.82; N, 12.35.

6,8-Dinitro-1-methyl-4-(2-methyl-1-oxo-2-propyl)-2-quinolone (3e) Yellow powder. mp 157–159 °C (dec.). IR (KBr/ cm^{-1}) 1724, 1682, 1539, 1344; $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 1.66 (s, 6H), 3.50 (s, 3H), 7.01 (s, 1H), 8.47 (d, $J=2.3$ Hz, 1H), 8.71 (d, $J=2.3$ Hz, 1H), 9.73 (s, 1H); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3) δ : 23.1 (q), 35.2 (q), 51.4 (s), 121.6 (d), 122.1 (s), 124.3 (d), 125.1 (d), 128.3 (s), 138.8 (s), 139.9 (s), 149.8 (s), 161.6 (s), 200.5 (d). *Anal.* Calcd for $\text{C}_{14}\text{H}_{13}\text{N}_3\text{O}_6 \cdot 1/3\text{H}_2\text{O}$: C, 51.70; H, 4.23; N, 12.92. Found: C, 51.65; H, 3.98; N, 12.58.

6,8-Dinitro-1-methyl-4-(2-oxo-cyclohexyl)-2-oxo-quinoline (3f) Pale yellow needles. mp 229–232 °C (dec.). IR (KBr/ cm^{-1}) 1703, 1668, 1531, 1344; $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 1.86–2.01 (m, 2H), 2.11–2.22 (m, 2H), 2.31–2.35 (m, 1H), 2.40–2.44 (m, 1H), 2.67–2.71 (m, 2H), 3.48 (s, 3H), 4.10 (dd, $J=12.5$, 4.8 Hz, 1H), 6.78 (s, 1H), 8.36 (d, $J=2.5$ Hz, 1H), 8.69 (d, $J=2.5$ Hz, 1H); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3) δ : 25.2 (t), 27.7 (t), 32.4 (t), 34.9 (q), 42.5 (t), 52.7 (d), 121.6 (d), 123.3 (d), 123.5 (d), 123.8 (s), 138.1 (s), 139.4 (s), 140.0 (s), 147.1 (s), 161.7 (s), 207.4 (s). *Anal.* Calcd for $\text{C}_{16}\text{H}_{15}\text{N}_3\text{O}_6 \cdot 1/4\text{H}_2\text{O}$: C, 54.94; H, 4.47; N, 12.01. Found: C, 54.62; H, 4.20; N, 12.12.

6,8-Dinitro-1-methyl-4-(2-oxopropyl)-2-quinolone (3g) Pale yellow needles. mp 157–158 °C (dec.). IR (KBr/ cm^{-1}) 1722, 1684, 1547, 1527, 1362, 1348, 1336; $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 2.43 (s, 3H), 3.49 (s, 3H), 4.06 (s, 2H), 6.79 (s, 1H), 8.47 (d, $J=2.5$ Hz, 1H), 8.71 (d, $J=2.5$ Hz, 1H); $^{13}\text{C-NMR}$ (100 MHz, CDCl_3) δ : 30.3 (q), 34.9 (q), 47.3 (t), 122.0 (d), 123.6 (s), 124.1 (d), 125.8 (d), 138.1 (s), 139.3 (s), 140.3 (s), 142.8 (s), 161.4 (s), 202.2 (s). *Anal.* Calcd for $\text{C}_{13}\text{H}_{11}\text{N}_3\text{O}_6$: C, 51.15; H, 3.63; N, 13.76. Found: C, 51.00; H, 3.55; N, 13.71.

6,8-Dinitro-1-methyl-4-(3-oxo-2-butyl)-2-quinolone (3h) and 6,8-Dinitro-1-methyl-4-(2-oxobutyl)-2-quinolone (3i) These products were obtained as a mixture, and their yields were determined by $^1\text{H-NMR}$. $^1\text{H-NMR}$ (400 MHz, CDCl_3) **3h** δ : 1.62 (d, $J=7.0$ Hz, 3H), 2.27 (s, 3H), 3.45 (s, 3H), 4.23 (q, $J=7.0$ Hz, 1H), 6.77 (s, 1H), 8.63 (s, 2H); **3i** δ : 1.15 (t, $J=7.0$ Hz, 3H), 2.71 (q, $J=7.0$ Hz, 2H), 3.45 (s, 3H), 4.03 (s, 2H), 6.71 (s, 1H), 8.63 (s, 2H).

6,8-Dinitro-1-methyl-4-(3-oxo-2-pentyl)-2-quinolone (3j) Yellow oil. IR (KBr/cm⁻¹) 1716, 1682, 1539, 1348; ¹H-NMR (400 MHz, CDCl₃) δ: 1.10 (t, *J*=7.2 Hz, 3H), 1.63 (d, *J*=7.0 Hz, 3H), 2.64 (q, *J*=7.2 Hz, 2H), 3.48 (s, 3H), 4.31 (q, *J*=7.0 Hz, 1H), 6.84 (s, 1H), 8.73 (s, 2H); ¹³C-NMR (100 MHz, CDCl₃) δ: 7.9 (q), 16.2 (q), 34.3 (t), 34.9 (q), 48.0 (d), 121.9 (d), 123.2 (s), 123.2 (d), 123.2 (d), 138.2 (s), 139.4 (s), 140.2 (s), 148.1 (s), 161.5 (s), 208.4 (s).

4-(3,4-Benzo-2-oxocyclohexyl)-6,8-dinitro-1-methyl-2-quinolone (3m) Pale orange needles. mp 227–229 °C (dec.). IR (KBr/cm⁻¹) 1675, 1539, 1525, 1340; ¹H-NMR (400 MHz, CDCl₃) δ: 2.52 (dddd, *J*=12.7, 4.1, 4.1, 3.8 Hz, 1H), 2.63 (dddd, *J*=12.7, 12.0, 4.0 Hz, 1H), 3.44 (ddd, *J*=16.7, 3.8, 4.0 Hz, 1H), 3.35 (ddd, *J*=16.7, 12.0, 4.1 Hz, 1H), 3.49 (s, 3H), 4.33 (dd, *J*=12.7, 4.1 Hz, 1H), 6.81 (s, 1H), 7.35–7.41 (m, 2H), 7.60 (t, *J*=6.8 Hz, 1H), 8.03 (d, *J*=7.6 Hz, 1H), 8.59 (d, *J*=2.4 Hz, 1H), 8.70 (d, *J*=2.4 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ: 27.9 (t), 29.3 (t), 35.0 (q), 50.0 (d), 121.7 (d), 123.0 (d), 124.2 (s), 124.2 (d), 127.3 (d), 128.1 (d), 129.0 (d), 131.8 (s), 134.6 (d), 138.0 (s), 139.3 (s), 140.2 (s), 143.5 (s), 148.3 (s), 161.7 (s), 194.9 (s). *Anal.* Calcd for C₂₀H₁₅N₃O₆: C, 61.07; H, 3.84; N, 10.69. Found: C, 59.83; H, 3.73; N, 10.28.

6,8-Dinitro-1-methyl-4-{2-oxo-2-(2-pyridyl)ethyl}-2-quinolone (3n) Pale orange needles. mp. 201–203 °C (dec.). IR (KBr/cm⁻¹) 1695, 1680, 1538, 1340; ¹H-NMR (400 MHz, CDCl₃) δ: 3.49 (s, 3H), 4.89 (s, 2H), 6.96 (s, 1H), 7.62 (ddd, *J*=7.7, 4.7, 0.9 Hz, 1H), 7.93 (ddd, *J*=7.7, 7.7, 1.7 Hz, 1H), 8.08 (dd, *J*=7.7, 0.9 Hz, 1H), 8.70 (d, *J*=2.5 Hz, 1H), 8.83 (dd, *J*=4.7, 1.7 Hz, 1H), 8.90 (d, *J*=2.5 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ: 34.9 (q), 40.8 (t), 121.9 (d), 122.7 (d), 124.0 (s), 124.7 (d), 126.3 (d), 128.4 (d), 137.5 (d), 138.1 (s), 139.2 (s), 140.3 (s), 144.2 (s), 149.4 (d), 151.8 (s), 161.5 (s), 196.4 (s). *Anal.* Calcd for C₁₇H₁₂N₄O₆: C, 55.44; H, 3.28; N, 15.21. Found: C, 55.49; H, 3.19; N, 15.15.

6,8-Dinitro-1-methyl-4-{2-oxo-2-(2-furyl)ethyl}-2-quinolone (3o) Pale yellow needles. mp. 212–214 °C (dec.). IR (KBr/cm⁻¹) 1670, 1541, 1335; ¹H-NMR (400 MHz, CDCl₃) δ: 3.49 (s, 3H), 4.47 (s, 2H), 6.68 (dd, *J*=3.6, 1.7 Hz, 1H), 6.92 (s, 1H), 7.39 (dd, *J*=3.6, 0.6 Hz, 1H), 7.73 (dd, *J*=1.7, 0.6 Hz, 1H), 8.72 (d, *J*=2.5 Hz, 1H), 8.73 (d, *J*=2.5 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ: 34.4 (q), 42.0 (t), 113.4 (d), 118.9 (d), 122.0 (d), 123.8 (s), 124.5 (d), 126.3 (d), 138.1 (s), 139.2 (s), 140.3 (s), 142.8 (s), 147.5 (d), 151.6 (s), 161.4 (s), 182.9 (s). *Anal.* Calcd for C₁₆H₁₁N₃O₇: C, 53.79; H, 3.10; N, 11.76. Found: C, 52.76; H, 2.91; N, 11.65.

References

- Ito C., *Nat. Med.*, **54**, 117–122 (2000).
- Grundon M. F., *Nat. Prod. Rep.*, **7**, 131–138 (1990).
- Grundon M. F., "The Alkaloids: Quinoline Alkaloids Related to Anthranic Acid," Vol. 32, Academic Press, London, 1968, pp. 341–439.
- Klasek A., Koristek K., Sedmera P., Halada P., *Heterocycles*, **60**, 799–815 (2003).
- Kumar R. N., Selvi S. T., Suresh T., Mohan P. S., *Heterocycles*, **57**, 357–360 (2002).
- McLaughlin M. J., Hsung R. P., *J. Org. Chem.*, **66**, 1049–1053 (2001).
- Lee Y. R., Kweon H. I., Koh W. S., Min K. R., Kim Y., Lee S. H., *Synthesis*, **2001**, 1851–1855 (2001).
- Bar G., Parsons A. F., Thomas C. B., *Tetrahedron*, **57**, 4719–4728 (2001).
- Boyd D. R., Sharma N. D., Barr S. A., Caroll J. G., Mackerracher D., Maolone J. F., *J. Chem. Soc., Perkin Trans. 1*, **2000**, 3397–3405 (2000).
- Ito C., Kondo Y., Wu T.-S., Furukawa H., *Chem. Pharm. Bull.*, **48**, 65–70 (2000).
- Kamperdick C., Van N., Sung T. V., Adam G., *Phytochemistry*, **50**, 177–181 (1999).
- Michael J. P., *Nat. Prod. Rep.*, **16**, 697–709 (1999).
- Atta-ur-Rahman, Sultana N., Choudhary M. I., Shah P. M., Khan M. R., *J. Nat. Prod.*, **61**, 713–717 (1998).
- Chen I.-S., Tsai I.-W., Teng C.-M., Chen J.-J., Chen J.-J., Chang Y.-L., Ko F.-N., Lu M. C., Pezzuto J. M., *Phytochemistry*, **46**, 525–529 (1997).
- Brader G., Bacher M., Greger H., Hofer O., *Phytochemistry*, **42**, 881–884 (1996).
- Kumabe R., Nishino H., *Tetrahedron Lett.*, **45**, 703–706 (2004).
- Majumdar K. C., Mukhopadhyay P. P., *Synthesis*, **2003**, 97–100 (2003).
- Täubel A. E., Langhans K., Kappe T., Stadlbauer W., *J. Heterocycl. Chem.*, **39**, 1259–1264 (2002).
- Nair V., Vinod A. U., Ramesh R., Menon R. S., Varma L., Mathew S., Chiaroni A., *Heterocycles*, **58**, 147–151 (2002).
- Ghosh M., Jana M., *Synthesis*, **2002**, 669–673 (2002).
- Bar G., Parsons A. F., Thomas C. B., *Chem. Commun.*, **2001**, 1350–1351 (2001).
- Lee Y. R., Suk J. Y., Kim B. S., *Org. Lett.*, **2**, 1387–1389 (2000).
- Hojas G., Fiala W., Stadlbauer W., *J. Heterocycl. Chem.*, **37**, 1559–1569 (2000).
- Pirrung M. C., Blume F., *J. Org. Chem.*, **64**, 3642–3649 (1999).
- Ye J.-H., Ling K.-Q., Zhang Y., Li N., Xu J.-H., *J. Chem. Soc., Perkin Trans. 1*, **1999**, 2017–2023 (1999).
- Majumdar K. C., Kundu A. K., Biswas P., *Heterocycles*, **51**, 2399–2406 (1999).
- Toche R. B., Jachak M. N., Sabnis R. W., Kappe T., *J. Heterocycl. Chem.*, **36**, 467–471 (1999).
- Mitsos C., Petrou J., Igglessi-Markopoulou O., *J. Heterocycl. Chem.*, **36**, 881–887 (1999).
- Tagawa Y., Kawaoka T., Goto Y., *J. Heterocycl. Chem.*, **34**, 1677–1683 (1997).
- Fujita R., Oikawa K., Yoshisuji T., Okuyama Y., Nakano H., Matsuzaki H., *Chem. Pharm. Bull.*, **51**, 295–300 (2003).
- Fujita R., Watanabe K., Yoshisuji T., Kabuto C., Matsuzaki H., Hongo H., *Chem. Pharm. Bull.*, **49**, 893–899 (2001).
- Fujita R., Watanabe K., Yoshisuji T., Hongo H., Matsuzaki H., *Chem. Pharm. Bull.*, **49**, 900–904 (2001).
- Nishiwaki N., Tanaka A., Uchida M., Tohda Y., Ariga M., *Bull. Chem. Soc. Jpn.*, **69**, 1377–1381 (1996).
- Nishiwaki N., Tanaka C., Asahara M., Asaka N., Tohda Y., Ariga M., *Heterocycles*, **51**, 567–574 (1999).
- Nishiwaki N., Sakashita M., Azuma M., Tanaka C., Tamura M., Asaka N., Hori K., Tohda Y., Ariga M., *Tetrahedron*, **58**, 473–478 (2002).
- Prill E. A., McElvain S. M., *Org. Synth., Coll. Vol. 2*, 419–421 (1943).